BioClonal in AIS Congress & MabDesign F. in Montpellier

2022 Oct 16
Our Business Development Manager, Paula Garfella Lorente, and part of BioClonal technical team are back to work loaded with energy & high level knowledge.

This international congress is organized by LabEx MAbImprove and the industrial organization MabDesign. It is part of the series of Industrial Symposia organized by MAbImprove since 2013, whose previous topics were: Antibodies Biosimilars, MAbDosing, MAbDelivery, Current & Next Generation Antibody Formats, Antibody Drug Conjugates, Targets for Mabs, Harnessing the Immune System with Abs, and Multispecific Abs, Ab-like molecules and adoptive cell therapy for fighting diseases.

Biobetters are protein-based therapeutics by improving their properties such as specificity for the target epitope, their developability or stability against degradation their degradation in future applications.

Red Mabs: A real solution for the therapeutic mAbs Patent Cliff.

Patent Cliff on antibody-based therapeutics is a major issue facing the pharmaceutical industry. The generation of improved therapeutic mAbs against the same epitope of the target molecule means enhancing its therapeutic capabilities which allows its patenting process. Red mAabs, developed by BioClonal, provides better analogous monoclonal antibodies ('Real Biobetters') against the same epitope with significant affinity, specificity and desarrollability improvements.
Image for BioClonal in AIS Congress & MabDesign F. in Montpellier
financiado por la Unión Europea - NextGenerationEU